CYP cynata therapeutics limited

Paving the way for next-gen treatments

  1. 495 Posts.
    lightbulb Created with Sketch. 148

    Mesenchymal stem cells (MSCs) are making waves in cell therapy, thanks to their ability to regenerate tissue and modulate the immune system without triggering severe reactions—a stark contrast to therapies like CAR T cells. Yet, their clinical use has been hampered by inconsistent production and the need for continuous tissue donations. Now, the Cymerus™ platform from the University of Wisconsin–Madison and Cynata Therapeutics is changing the game. By harnessing induced pluripotent stem cells (iPSCs), this breakthrough method allows for scalable, reproducible MSC manufacturing—paving the way for next-gen treatments for conditions like osteoarthritis.

    https://www.impactlab.com/2025/05/15/advancing-msc-based-therapies-overcoming-manufacturing-barriers-with-the-cymerus-platform/

    https://x.com/ThomasFrey/status/1923930325698195875

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
17.0¢
Change
-0.005(2.86%)
Mkt cap ! $38.41M
Open High Low Value Volume
18.0¢ 18.0¢ 16.5¢ $41.91K 247.1K

Buyers (Bids)

No. Vol. Price($)
2 8275 17.0¢
 

Sellers (Offers)

Price($) Vol. No.
17.5¢ 3700 1
View Market Depth
Last trade - 16.10pm 30/07/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.